The University of Chicago Header Logo

Ardaman Shergill

Concepts (170)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Appendiceal Neoplasms
17
2026
55
5.210
Why?
Peritoneal Neoplasms
18
2026
196
3.240
Why?
Circulating Tumor DNA
6
2026
82
2.700
Why?
Colorectal Neoplasms
15
2026
1120
2.320
Why?
Antineoplastic Combined Chemotherapy Protocols
21
2026
2666
2.020
Why?
Adenocarcinoma
10
2026
1215
1.880
Why?
Neoplasm Recurrence, Local
7
2026
1538
1.800
Why?
Hyperthermia, Induced
9
2026
77
1.650
Why?
Colonic Neoplasms
8
2026
592
1.620
Why?
Rectal Neoplasms
7
2026
139
1.330
Why?
Biomarkers, Tumor
6
2026
1786
1.180
Why?
Chromogranins
1
2026
17
0.930
Why?
GTP-Binding Protein alpha Subunits, Gs
1
2026
24
0.930
Why?
Fluorouracil
9
2026
543
0.870
Why?
Mutation
8
2026
4443
0.760
Why?
Cytoreduction Surgical Procedures
16
2025
105
0.750
Why?
Neoplasm Staging
8
2026
2087
0.610
Why?
Survival Rate
9
2026
2057
0.580
Why?
Precision Medicine
1
2024
512
0.580
Why?
Celecoxib
3
2026
34
0.480
Why?
Practice Guidelines as Topic
5
2025
1116
0.470
Why?
Neoadjuvant Therapy
5
2026
477
0.460
Why?
Humans
51
2026
98799
0.450
Why?
Retrospective Studies
16
2026
11104
0.450
Why?
Prognosis
8
2026
4139
0.450
Why?
Middle Aged
22
2026
29642
0.440
Why?
Class I Phosphatidylinositol 3-Kinases
2
2026
84
0.430
Why?
Male
25
2026
47475
0.410
Why?
Female
26
2026
51997
0.390
Why?
Aged
17
2026
21986
0.380
Why?
Follow-Up Studies
5
2026
4049
0.380
Why?
Leucovorin
7
2026
205
0.380
Why?
Pancreatic Neoplasms
3
2024
782
0.370
Why?
Adult
17
2026
29698
0.370
Why?
Delphi Technique
6
2025
183
0.310
Why?
Radiosurgery
2
2024
352
0.310
Why?
Consensus
6
2025
308
0.300
Why?
Liver Neoplasms
3
2024
840
0.280
Why?
DNA Mismatch Repair
2
2026
60
0.280
Why?
Antibodies, Monoclonal, Humanized
2
2026
1105
0.280
Why?
Aged, 80 and over
6
2025
7461
0.280
Why?
Capecitabine
2
2026
103
0.270
Why?
Microsatellite Instability
3
2024
69
0.270
Why?
Age of Onset
2
2026
369
0.270
Why?
Organoplatinum Compounds
5
2026
95
0.270
Why?
Disease-Free Survival
6
2026
1196
0.260
Why?
Combined Modality Therapy
7
2024
1754
0.250
Why?
Phenylurea Compounds
2
2024
112
0.240
Why?
Cholecalciferol
1
2026
37
0.240
Why?
Chemotherapy, Adjuvant
5
2026
527
0.240
Why?
Pelvis
1
2026
106
0.230
Why?
MutS Homolog 2 Protein
1
2024
33
0.210
Why?
Watchful Waiting
1
2025
77
0.210
Why?
Cyclooxygenase 2 Inhibitors
1
2024
36
0.210
Why?
Patient Preference
1
2025
136
0.200
Why?
Quinolines
1
2024
97
0.200
Why?
Peritoneum
4
2024
52
0.200
Why?
Surgical Oncology
1
2023
34
0.190
Why?
Patient Participation
1
2025
251
0.190
Why?
Mutation, Missense
1
2024
312
0.190
Why?
Appendix
1
2023
33
0.190
Why?
Vaccines
1
2024
86
0.190
Why?
Cancer Vaccines
1
2024
168
0.180
Why?
Quality Assurance, Health Care
1
2024
229
0.180
Why?
Neuroendocrine Tumors
1
2024
158
0.180
Why?
Antineoplastic Agents
2
2024
2386
0.180
Why?
C-Reactive Protein
1
2023
219
0.170
Why?
Molecular Targeted Therapy
1
2024
331
0.170
Why?
Ataxia Telangiectasia Mutated Proteins
1
2021
65
0.170
Why?
Research Design
1
2025
652
0.170
Why?
DNA Breaks, Double-Stranded
1
2021
73
0.170
Why?
Palliative Care
1
2023
291
0.170
Why?
Germ-Line Mutation
1
2024
404
0.170
Why?
Lung Neoplasms
2
2023
2474
0.160
Why?
Mitoxantrone
1
2020
65
0.150
Why?
Clinical Trials as Topic
1
2025
1128
0.150
Why?
Tumor Microenvironment
1
2024
621
0.150
Why?
Biomedical Research
1
2025
477
0.150
Why?
Etoposide
1
2020
207
0.150
Why?
Cytarabine
1
2020
218
0.150
Why?
Pyridines
3
2024
317
0.130
Why?
Protein Kinase Inhibitors
1
2021
642
0.130
Why?
Neoplasms
2
2024
3382
0.120
Why?
Double-Blind Method
3
2026
1793
0.120
Why?
Kaplan-Meier Estimate
3
2025
909
0.120
Why?
Head and Neck Neoplasms
1
2021
1091
0.100
Why?
Carcinoma, Non-Small-Cell Lung
1
2023
1177
0.100
Why?
Magnetic Resonance Imaging
1
2026
3622
0.100
Why?
Leukemia, Myeloid, Acute
1
2020
850
0.100
Why?
Myeloproliferative Disorders
1
2016
159
0.100
Why?
Chemotherapy, Cancer, Regional Perfusion
2
2023
18
0.100
Why?
Neoplasm Grading
2
2024
425
0.090
Why?
Carcinoembryonic Antigen
2
2023
40
0.090
Why?
Treatment Outcome
4
2026
9806
0.080
Why?
Prospective Studies
3
2024
4837
0.080
Why?
Hypertension
2
2026
791
0.070
Why?
Recurrence
2
2023
1274
0.070
Why?
Immunotherapy
2
2024
831
0.060
Why?
Mitomycin
1
2026
30
0.060
Why?
Cohort Studies
2
2023
3242
0.060
Why?
Neutropenia
1
2026
211
0.060
Why?
Camptothecin
1
2026
198
0.060
Why?
Bevacizumab
1
2026
255
0.060
Why?
Quality of Life
2
2024
1904
0.050
Why?
Anilides
1
2024
50
0.050
Why?
Colectomy
1
2026
211
0.050
Why?
Tumor Cells, Cultured
1
2026
1029
0.050
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
1
2024
54
0.050
Why?
Cisplatin
1
2026
578
0.050
Why?
Thromboembolism
1
2024
123
0.050
Why?
Standard of Care
1
2024
71
0.050
Why?
B7-H1 Antigen
1
2026
333
0.050
Why?
Trifluridine
1
2023
2
0.050
Why?
Diarrhea
1
2024
180
0.050
Why?
Benzofurans
1
2023
12
0.050
Why?
Fatigue
1
2024
187
0.050
Why?
Advance Directives
1
2023
64
0.050
Why?
Preoperative Period
1
2023
103
0.050
Why?
Organ Sparing Treatments
1
2023
54
0.050
Why?
Proto-Oncogene Proteins p21(ras)
1
2024
186
0.050
Why?
HLA Antigens
1
2024
239
0.050
Why?
Anal Canal
1
2023
94
0.050
Why?
Dose-Response Relationship, Drug
1
2026
1949
0.050
Why?
Radiotherapy Planning, Computer-Assisted
1
2024
215
0.040
Why?
Sex Factors
1
2025
1144
0.040
Why?
Liquid Biopsy
1
2022
51
0.040
Why?
Monoterpenes
1
2022
6
0.040
Why?
Neoplasm Metastasis
1
2026
1102
0.040
Why?
Quinazolines
1
2023
222
0.040
Why?
Carcinoma, Pancreatic Ductal
1
2024
158
0.040
Why?
GPI-Linked Proteins
1
2022
58
0.040
Why?
Tumor Suppressor p53-Binding Protein 1
1
2021
13
0.040
Why?
G2 Phase Cell Cycle Checkpoints
1
2021
14
0.040
Why?
Antigens, Neoplasm
1
2024
366
0.040
Why?
Phosphatidylinositol 3-Kinases
1
2023
286
0.040
Why?
Drug Resistance, Neoplasm
1
2026
671
0.040
Why?
Incidence
1
2026
1798
0.040
Why?
Interleukin-6
1
2023
283
0.040
Why?
Drug Combinations
1
2022
202
0.040
Why?
Vascular Endothelial Growth Factor A
1
2023
402
0.040
Why?
Immunologic Factors
1
2022
180
0.040
Why?
Preoperative Care
1
2023
420
0.040
Why?
Chemoradiotherapy
1
2023
337
0.040
Why?
Young Adult
2
2026
7598
0.040
Why?
Tumor Burden
1
2021
330
0.040
Why?
Postoperative Period
1
2021
325
0.040
Why?
Administration, Oral
1
2022
677
0.040
Why?
Mice, Nude
1
2021
829
0.040
Why?
Xenograft Model Antitumor Assays
1
2021
559
0.040
Why?
Tumor Suppressor Protein p53
1
2023
470
0.040
Why?
Chronic Disease
1
2023
991
0.040
Why?
Prevalence
1
2023
1396
0.040
Why?
Biopsy
1
2023
1226
0.040
Why?
Cell Cycle Proteins
1
2021
420
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2023
588
0.030
Why?
Disease Progression
1
2023
1621
0.030
Why?
Length of Stay
1
2021
889
0.030
Why?
Surveys and Questionnaires
1
2025
3058
0.030
Why?
Inflammation
1
2023
1134
0.030
Why?
Biomarkers
1
2023
2026
0.030
Why?
Cell Proliferation
1
2021
1801
0.030
Why?
Apoptosis
1
2021
1754
0.030
Why?
Cell Line, Tumor
1
2021
2913
0.030
Why?
Illinois
1
2016
531
0.030
Why?
Adolescent
1
2026
10168
0.020
Why?
United States
1
2025
8387
0.020
Why?
Signal Transduction
1
2021
3642
0.020
Why?
Postoperative Complications
1
2021
2719
0.020
Why?
Mice
1
2021
12762
0.020
Why?
Animals
1
2021
29045
0.010
Why?
Shergill's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (170)
Explore
_
Co-Authors (34)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_